GenomOncology Pathology Workbench to support OmniSeq INSIGHT℠, a genomic and immune profiling test that identifies potential treatment and clinical trial options for solid tumors

CLEVELAND, Jan. 12, 2022 — GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp's OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors.

Labcorp to announce fourth quarter and full year 2021 financial results on February 10, 2022

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 10, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2021 before the market opens on Thursday, February 10, 2022 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Labcorp to speak virtually at the 40th annual J.P. Morgan Healthcare conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 4, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11 at 4:30 p.m. (ET).

Labcorp strengthens oncology leadership position with the addition of Personal Genome Diagnostics, a provider of comprehensive liquid biopsy and tissue-based genomic products and services

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 23, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.